|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LZTR1 |
Gene summary for LZTR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LZTR1 | Gene ID | 8216 |
| Gene name | leucine zipper like transcription regulator 1 | |
| Gene Alias | BTBD29 | |
| Cytomap | 22q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8N653 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8216 | LZTR1 | C04 | Human | Oral cavity | OSCC | 1.35e-11 | 5.53e-01 | 0.2633 |
| 8216 | LZTR1 | C21 | Human | Oral cavity | OSCC | 3.90e-06 | 2.56e-01 | 0.2678 |
| 8216 | LZTR1 | C30 | Human | Oral cavity | OSCC | 1.06e-13 | 5.72e-01 | 0.3055 |
| 8216 | LZTR1 | C43 | Human | Oral cavity | OSCC | 4.17e-02 | 1.13e-01 | 0.1704 |
| 8216 | LZTR1 | C46 | Human | Oral cavity | OSCC | 5.02e-05 | 9.39e-02 | 0.1673 |
| 8216 | LZTR1 | C51 | Human | Oral cavity | OSCC | 7.72e-13 | 4.33e-01 | 0.2674 |
| 8216 | LZTR1 | SYSMH2 | Human | Oral cavity | OSCC | 8.93e-12 | 3.43e-01 | 0.2326 |
| 8216 | LZTR1 | SYSMH3 | Human | Oral cavity | OSCC | 4.64e-08 | 2.46e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00072659 | Oral cavity | OSCC | Ras protein signal transduction | 185/7305 | 337/18723 | 1.95e-09 | 4.60e-08 | 185 |
| GO:00465788 | Oral cavity | OSCC | regulation of Ras protein signal transduction | 90/7305 | 189/18723 | 9.58e-03 | 3.40e-02 | 90 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LZTR1 | SNV | Missense_Mutation | c.1862N>T | p.Ser621Phe | p.S621F | Q8N653 | protein_coding | deleterious(0.03) | possibly_damaging(0.804) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LZTR1 | SNV | Missense_Mutation | rs587777180 | c.1397N>A | p.Arg466Gln | p.R466Q | Q8N653 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| LZTR1 | SNV | Missense_Mutation | rs766345180 | c.1852N>A | p.Glu618Lys | p.E618K | Q8N653 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| LZTR1 | SNV | Missense_Mutation | rs757502214 | c.508C>T | p.Arg170Trp | p.R170W | Q8N653 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LZTR1 | SNV | Missense_Mutation | rs773016962 | c.856N>A | p.Gly286Arg | p.G286R | Q8N653 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
| LZTR1 | insertion | Frame_Shift_Ins | novel | c.288_289insATTA | p.Arg97IlefsTer50 | p.R97Ifs*50 | Q8N653 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| LZTR1 | insertion | Frame_Shift_Ins | novel | c.289_290insAGGCGCCTGCCACCATGCCA | p.Arg97GlnfsTer11 | p.R97Qfs*11 | Q8N653 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| LZTR1 | insertion | Nonsense_Mutation | novel | c.2233_2234insGGGTCATTGCTTTGTGTGACAGTTGAGCACAGACATGGAGGTACT | p.Ala745delinsGlyValIleAlaLeuCysAspSerTerAlaGlnThrTrpArgTyrSer | p.A745delinsGVIALCDS*AQTWRYS | Q8N653 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LZTR1 | insertion | Frame_Shift_Ins | novel | c.2351_2352insGGCACTGGACATG | p.Lys789GlyfsTer66 | p.K789Gfs*66 | Q8N653 | protein_coding | TCGA-E9-A1N8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| LZTR1 | deletion | Frame_Shift_Del | novel | c.245delT | p.Val82AspfsTer19 | p.V82Dfs*19 | Q8N653 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |